Viking Therapeutics Stock Total Debt
| VKTX Stock | USD 33.98 1.30 3.98% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Viking Therapeutics' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Viking Therapeutics Company Total Debt Analysis
Viking Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Viking Therapeutics Total Debt | 1.12 M |
Most of Viking Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viking Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Viking Therapeutics has a Total Debt of 1.12 M. This is 99.96% lower than that of the Biotechnology sector and 99.66% lower than that of the Health Care industry. The total debt for all United States stocks is 99.98% higher than that of the company.
Viking Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viking Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Viking Therapeutics could also be used in its relative valuation, which is a method of valuing Viking Therapeutics by comparing valuation metrics of similar companies.Viking Therapeutics is currently under evaluation in total debt category among its peers.
Viking Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 2.87 B | ||||
| Shares Outstanding | 112.44 M | ||||
| Shares Owned By Insiders | 2.14 % | ||||
| Shares Owned By Institutions | 70.08 % | ||||
| Number Of Shares Shorted | 28.6 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 4.62 X | ||||
| EBITDA | (109.52 M) | ||||
| Net Income | (109.96 M) | ||||
| Cash And Equivalents | 155.02 M | ||||
| Cash Per Share | 2.02 X | ||||
| Total Debt | 1.12 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 11.74 X | ||||
| Book Value Per Share | 7.08 X | ||||
| Cash Flow From Operations | (87.79 M) | ||||
| Short Ratio | 7.26 X | ||||
| Earnings Per Share | (1.54) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 89.95 | ||||
| Number Of Employees | 48 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 3.67 B | ||||
| Total Asset | 908.32 M | ||||
| Retained Earnings | (487.91 M) | ||||
| Working Capital | 879.8 M | ||||
| Current Asset | 15.2 M | ||||
| Current Liabilities | 1.98 M | ||||
| Net Asset | 908.32 M |
About Viking Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viking Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viking Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viking Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.